Lawson Kroeker Investment Management Inc. NE Sells 1,735 Shares of Thermo Fisher Scientific Inc. $TMO

04 Apr 2026, 06:46 by Doug Wharley · The Cerbat Gem

Lawson Kroeker Investment Management Inc. NE reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 11.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,047 shares of the medical research company’s stock after selling 1,735 shares during the quarter. Thermo Fisher Scientific comprises 2.4% of Lawson Kroeker Investment Management Inc. NE’s holdings, making the stock its 17th biggest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Thermo Fisher Scientific were worth $8,140,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of TMO. Capital World Investors boosted its stake in Thermo Fisher Scientific by 7.4% in the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock valued at $4,988,132,000 after acquiring an additional 706,572 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Thermo Fisher Scientific by 21.0% during the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after acquiring an additional 1,028,125 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock valued at $1,732,422,000 after purchasing an additional 1,262,967 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Thermo Fisher Scientific by 25.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,936,998 shares of the medical research company’s stock worth $1,424,503,000 after purchasing an additional 594,218 shares during the last quarter. Finally, Fisher Asset Management LLC increased its holdings in Thermo Fisher Scientific by 1.2% in the third quarter. Fisher Asset Management LLC now owns 2,721,101 shares of the medical research company’s stock valued at $1,319,789,000 after purchasing an additional 31,298 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.3%

NYSE TMO opened at $492.90 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The firm has a market cap of $183.10 billion, a P/E ratio of 27.78, a P/E/G ratio of 2.63 and a beta of 0.97. The stock’s 50-day moving average is $516.40 and its 200-day moving average is $547.68.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same period in the prior year, the business earned $6.10 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 7.2% compared to the same quarter last year. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be issued a dividend of $0.47 per share. The ex-dividend date is Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.60%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the sale, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Robert W. Baird set a $653.00 price target on Thermo Fisher Scientific in a research note on Friday, January 30th. Evercore reissued an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. Finally, KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price on the stock in a report on Sunday, December 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $632.50.

View Our Latest Stock Analysis on TMO

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.